Bioventus (BVS) Accounts Payables (2020 - 2026)

Bioventus (BVS) has reported Accounts Payables for 7 consecutive years, with $20.2 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Accounts Payables fell 16.7% year-over-year to $20.2 million; the trailing twelve-month figure through Jun 2026 stood at $20.2 million (down 16.7% YoY), and the FY2025 full-year result was $10.9 million, down 53.87% from the prior year.
• Accounts Payables eased to $20.2 million in Q2 2026 per BVS's latest filing, from $24.0 million in the prior quarter.
• Across five years, Accounts Payables topped out at $41.4 million in Q3 2023 and bottomed at $10.9 million in Q4 2025.
• Historically, Accounts Payables has averaged $23.8 million across 5 years, with a median of $23.4 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Accounts Payables soared 160.45% in 2022, then sank 53.87% in 2025.
• Over 5 years, Accounts Payables stood at $36.7 million in 2022, then plunged by 37.22% to $23.0 million in 2023, then grew by 2.83% to $23.7 million in 2024, then tumbled by 53.87% to $10.9 million in 2025, then surged by 84.81% to $20.2 million in 2026.
• According to Business Quant data, Accounts Payables over the past three periods registered $20.2 million, $24.0 million, and $10.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.